Targeting the ACE C-domain, while preserving the ACE N-domain, combined with NEP inhibition may be as effective as omapatrilat in lowering BP and cardiovascular protection but without injurious endothelial effects that predispose to microvascular leakage implicated in angioedema. Here, ACE is linked to angioedema.